CAS 83150-76-9

Octreotide acetate

Description:

Octreotide acetate is a synthetic octapeptide that mimics the natural hormone somatostatin, which plays a crucial role in regulating various physiological processes, including hormone secretion and gastrointestinal function. It is primarily used in the medical field to treat conditions such as acromegaly, certain types of neuroendocrine tumors, and severe diarrhea associated with carcinoid syndrome. The substance is characterized by its ability to inhibit the release of growth hormone and other hormones, thereby helping to manage symptoms related to hormone overproduction. Octreotide acetate is typically administered via subcutaneous or intramuscular injection and has a longer half-life compared to somatostatin, allowing for less frequent dosing. Its chemical structure includes a cyclic configuration that enhances its stability and potency. The acetate form improves solubility and bioavailability, making it suitable for therapeutic use. As with any medication, potential side effects may include gastrointestinal disturbances, injection site reactions, and alterations in glucose metabolism, necessitating careful monitoring during treatment.

Formula: C₄₉H₆₆N₁₀O₁₀S₂(C₂H₄O₂)

InChI: InChI=1/C49H66N10O10S2.C2H4O2/c1-28(61)39(25-60)56-48(68)41-27-71-70-26-40(57-43(63)34(51)21-30-13-5-3-6-14-30)47(67)54-37(22-31-15-7-4-8-16-31)45(65)55-38(23-32-24-52-35-18-10-9-17-33(32)35)46(66)53-36(19-11-12-20-50)44(64)59-42(29(2)62)49(69)58-41;1-2(3)4/h3-10,13-18,24,28-29,34,36-42,52,60-62H,11-12,19-23,25-27,50-51H2,1-2H3,(H,53,66)(H,54,67)(H,55,65)(H,56,68)(H,57,63)(H,58,69)(H,59,64);1H3,(H,3,4)/t28-,29-,34-,36+,37+,38-,39-,40+,41+,42+;/m1./s1

Synonyms:

• L-cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-(2-hydroxy-1-(hydroxymethyl) propyl)-cyclic (2->7)-disulfide, (R-(R*,R*))
• OctreotideAcetate
• 10-(4-aminobutyl)-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-19-(phenylalanylamino)-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide acetate (1:2)
• (4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-[(1R)-1-hydroxyethyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-19-(D-phenylalanylamino)-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide
• (4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-16-benzyl-N-[(2R,3R)-1,3-dihydroxybutan-2-yl]-7-(1-hydroxyethyl)-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-19-(D-phenylalanylamino)-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide
• 1: PN: EP1118336 SEQID: 1 claimed protein
• 11: PN: US20030229017 PAGE: 13 claimed protein
• 14: PN: DE10147056 PAGE: 40 claimed protein
• 17: PN: US6268342 SEQID: 18 claimed protein
• 25: PN: WO2007081792 SEQID: 40 claimed protein
• L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl]-, cyclic (2→7)-disulfide
• Longastatin
• Octreotide

Octreotide

CAS: 83150-76-9

A slow-release form of octreotide. Pamoate is the bivalent anion of pamoic acid (embonic acid, 4,4·-methylene-bis-(3-hydroxy-2-naphthoic acid)). CAS-number (octreotide pamoate): 135467-16-2.

Formula: C₄₉H₆₆N₁₀O₁₀S₂

Purity: > 98%

Molecular weight: 1019.26

Ref: 01-4076740

[R-(R*,R*)]-D-Phenylalanyl-L-cysteinyl-L-phenylalanyl-D-tryptophyl-L-lysyl-L-threonyl-N-[2-hydroxy-1-(hydroxy-methyl)propyl]-cysteinamide cyclic(2→7)-disulfide

CAS: 83150-76-9

Formula: C₄₉H₆₆N₁₀O₁₀S₂

Purity: 98%

Color and Shape: Solid

Molecular weight: 1019.2393

Ref: IN-DA003A7L

Octreotide-Phenylalanine-d8 Ditrifluoroacetate

CAS: 83150-76-9

Formula: C₄₉H₅₈D₈N₁₀O₁₀S₂·2C₂HF₃O₂

Molecular weight: 1027.30 2*114.02

Ref: 4Z-PO-036001

Octreotide

CAS: 83150-76-9

Formula: C₄₉H₆₆N₁₀O₁₀S₂

Molecular weight: 1019.24

Ref: 7W-GP4986

Octreotide

CAS: 83150-76-9

Octreotide

Purity: ≥98%

Molecular weight: 1019.24g/mol

Ref: 54-BUP00965

Octreotide

CAS: 83150-76-9

Octreotide (SMS 201-995) is a potent inhibitor of growth hormone, glucagon, and insulin.

Formula: C₄₉H₆₆N₁₀O₁₀S₂

Purity: 99.64%

Color and Shape: White Powder

Molecular weight: 1019.24

Ref: TM-T2584

Octreotide-phenylalanine-d8 di-Trifluoroacetic Acid Salt

Controlled Product

CAS: 83150-76-9

Applications Labelled octapeptide analog of Somatostatin. A gastric antisecretory agent. Used in treatment of acromegaly.
References Bauer, W., et al.: Life Sci., 31, 1133 (1982), Plewe, G., et al.: Lancet, 2, 782 (1984), Kraenzlin, M.E., et al.: Experientia, 41, 738 (1985), del Pozo, E., et al.: Acta Endocrinol., 111, 433 (1986),

Formula: C₅₃H₆₀D₈F₆N₁₀O₁₄S₂

Color and Shape: Neat

Molecular weight: 1255.34

Ref: TR-O239952

13C6-Lys Octreotide Trifluoroacetate

Controlled Product

CAS: 83150-76-9

Formula: C₄₃₁₃C₆H₆₆N₁₀O₁₀S₂•xC₂HF₃O₂

Color and Shape: White To Off-White

Molecular weight: 1025.2011402

Ref: TR-O239958

Octreotide

CAS: 83150-76-9

Octreotide is a drug that belongs to the macrocycle class of polymers. It is used in the treatment of cancer, as well as for diseases such as diabetes mellitus and acromegaly. Octreotide has been shown to inhibit p-glycoprotein (P-gp) and other drug transporters, which leads to an increase in oral bioavailability. In addition, octreotide also inhibits cellular proliferation by interfering with intracellular signalling pathways and protein synthesis. This drug has been shown to have a wide range of biochemical properties and is being investigated as an investigational agent for the treatment of various cancers.

Formula: C₄₉H₆₆N₁₀O₁₀S₂

Purity: Min. 95%

Molecular weight: 1,019.24 g/mol

Ref: 3D-OCT-3738-PI

Octreotide

CAS: 83150-76-9

Octreotide is a synthetic somatostatin analogue used for the treatment of acromegaly and neuroendocrine tumours. In clinical settings, Octreotide is used for the treatment of vasoactive intestinal peptide-secreting tumours, growth hormone producing tumours, and pituitary tumours. Octreotide also displays efficacy in the treatment of cluster headaches, acute haemorrhage from liver cirrhosis, malignant bowel obstruction, and idiopathic intracranial hypertension. Octreotide exerts its organ protective effects through several mechanisms, including its ability to decrease the levels of endotoxin and the proinflammatory cytokines TNF-alpha and IL-1β, and by inhibiting hepatocellular apoptosis. Octreotide also exerts a protective effect in hepatic ischemia-reperfusion (HIR) injury, which often occurs after complex liver surgeries such as major resection or transplantation.

Molecular weight: 1,018.4 g/mol

Ref: 3D-CRB1001491